H
Hans J Moebius
Researcher at AMAG Pharmaceuticals
Publications - 16
Citations - 604
Hans J Moebius is an academic researcher from AMAG Pharmaceuticals. The author has contributed to research in topics: Medicine & Placebo. The author has an hindex of 6, co-authored 9 publications receiving 435 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Serge Gauthier,Howard Feldman,Lon S. Schneider,Gordon K. Wilcock,Giovanni B. Frisoni,Jiri Hardlund,Hans J Moebius,Peter Bentham,Karin A Kook,Damon Wischik,Bjoern Schelter,Charles S Davis,Roger T. Staff,Luc Bracoud,Kohkan Shamsi,John Storey,Charles R. Harrington,Claude M. Wischik +17 more
TL;DR: The primary analysis for this study was negative, and the results do not suggest benefit of LMTM as an add-on treatment for mild to moderate Alzheimer's disease, but the prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes.
Journal ArticleDOI
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Gordon K. Wilcock,Serge Gauthier,Giovanni B. Frisoni,Jianping Jia,Jiri Hardlund,Hans J Moebius,Peter Bentham,Karin A Kook,Bjoern Schelter,Damon Wischik,Charles S Davis,Roger T. Staff,Vesna Vuksanović,Trevor Ahearn,Luc Bracoud,Kohkan Shamsi,Ken Marek,John Seibyl,Gernot Riedel,John Storey,Charles R. Harrington,Claude M. Wischik +21 more
TL;DR: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Richard S.E. Keefe,Herbert A Meltzer,Nancy Dgetluck,Maria Gawryl,Gerhard Koenig,Hans J Moebius,Ilise Lombardo,Dana Hilt +7 more
TL;DR: Overall, encenicline was generally well tolerated and demonstrated clinically meaningful improvements in cognition and function in patients with schizophrenia.
Journal ArticleDOI
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Helen Shiells,Bjoern Schelter,Peter Bentham,Thomas C. Baddeley,Christopher M. Rubino,Harish Ganesan,Jeffrey P. Hammel,Vesna Vuksanović,Roger T. Staff,Alison D. Murray,Luc Bracoud,Damon Wischik,Gernot Riedel,Serge Gauthier,Jianping Jia,Hans J Moebius,Jiri Hardlund,Christopher M. Kipps,Karin A Kook,John Storey,Charles R. Harrington,Claude M. Wischik +21 more
TL;DR: Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain atrophy at the 8 mg/day dose in bvFTD as recently reported in AD.
Journal ArticleDOI
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
Peter A. Ljubenkov,Lauren Edwards,Leonardo Iaccarino,Renaud La Joie,Julio C. Rojas,Mary Koestler,Baruch Harris,Bradley F. Boeve,Barbara Borroni,John C. van Swieten,Murray Grossman,Florence Pasquier,Giovanni B. Frisoni,Catherine J. Mummery,Rik Vandenberghe,Rik Vandenberghe,Isabelle Le Ber,Didier Hannequin,Scott M. McGinnis,Sophie Auriacombe,Marco Onofrj,Ira J. Goodman,Henry Riordan,Gary Wisniewski,Jacob Hesterman,Ken Marek,Beth Ann Haynes,Holger Patzke,Gerhard Koenig,Dana Hilt,Hans J Moebius,Adam L. Boxer +31 more
TL;DR: The first randomized clinical trial of a histone deacetylase inhibitor in frontotemporal dementia (FTD) resulting from progranulin (GRN) gene variations was described in this article.